Cellectis (CLLS) Common Equity (2014 - 2026)

Cellectis' Common Equity history runs 13 years deep, the most recent figure standing at $59.9 million for Q1 2026.

• On a quarterly basis, Common Equity fell 48.44% year-over-year to $59.9 million in Q1 2026; TTM through Mar 2026 was $59.9 million, a 48.44% decrease from a year earlier, with the FY2025 full-year figure at $75.9 million, down 42.07% from the prior year.
• Common Equity slipped to $59.9 million in Q1 2026 per CLLS's latest filing, from $75.9 million in the prior quarter.
• Across five years, Common Equity topped out at $191.0 million in Q1 2022 and bottomed at $59.9 million in Q1 2026.
• The 5-year median for Common Equity is $113.7 million (2023), against an average of $115.0 million.
• Across the five-year window, Common Equity soared 70.02% in 2024 and tumbled 48.44% in 2026, its largest moves.
• Year by year, Common Equity stood at $125.9 million in 2022, then sank by 32.75% to $84.7 million in 2023, then surged by 54.71% to $131.0 million in 2024, then slumped by 42.07% to $75.9 million in 2025, then declined by 21.06% to $59.9 million in 2026.
• Per Business Quant, the three latest CLLS Common Equity figures stand at $59.9 million (Q1 2026), $75.9 million (Q4 2025), and $100.5 million (Q3 2025).